XORTX Therapeutics, Inc.
(Canadian National Stock Exchange : XRTX)

( )
XRTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. 1.96%81.050.7%$1593.78m
JNJJohnson & Johnson -0.09%163.720.7%$1029.28m
PFEPfizer Inc. 1.76%42.830.9%$940.36m
ABBVAbbVie, Inc. 0.97%108.491.9%$680.09m
BMYBristol-Myers Squibb Co. 0.87%58.091.0%$658.95m
LLYEli Lilly & Co. 0.64%243.851.1%$610.94m
AZNAstraZeneca Plc 0.77%60.631.0%$366.84m
NVSNovartis AG 1.61%84.490.2%$176.86m
GSKGlaxoSmithKline Plc 0.74%39.460.2%$161.96m
RGENRepligen Corp. 2.13%268.256.8%$118.08m
AVIRAtea Pharmaceuticals, Inc. -4.20%13.240.3%$116.76m
VTRSViatris, Inc. 3.10%13.990.0%$92.80m
NVONovo Nordisk A/S -0.09%104.560.1%$91.61m
EDSAEdesa Biotech, Inc. -0.97%8.140.0%$73.37m
SNYSanofi 2.06%49.050.2%$64.75m

Company Profile

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.